These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11098584)

  • 1. [Prostate cancer: at the beginning of a new millennium].
    Tombal B; Van Cangh PJ
    Acta Urol Belg; 2000; 68(2):29-33. PubMed ID: 11098584
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinics in prostate cancer].
    Sugimura Y
    Rinsho Byori; 2004 Jul; 52(7):604-10. PubMed ID: 15344560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [5/7 Prostate cancer in the elderly man].
    Mourey L
    Soins Gerontol; 2010; (86):45-6. PubMed ID: 21298971
    [No Abstract]   [Full Text] [Related]  

  • 4. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prostate cancer: view of the horizon].
    Dauriac P
    Rev Infirm; 2004 Mar; (99):18-9. PubMed ID: 15124488
    [No Abstract]   [Full Text] [Related]  

  • 6. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
    Carlucci JR; Nabizada-Pace F; Samadi DB
    Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the benefit justify the risk?
    Albertsen PC
    J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059
    [No Abstract]   [Full Text] [Related]  

  • 8. Current Opinion in Urology. Prostate cancer. Current world literature.
    Curr Opin Urol; 2009 May; 19(3):327-34. PubMed ID: 19363350
    [No Abstract]   [Full Text] [Related]  

  • 9. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GnRH analogues in the treatment of prostate cancer].
    Zerbib M
    Rev Prat; 2005; Spec. No():35-41. PubMed ID: 15822870
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
    Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
    Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caring for a patient with metastatic prostate cancer.
    Held-Warmkessel J
    Nursing; 2008 Jun; 38(6):52-6. PubMed ID: 18497662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 18. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
    Uphoff J; Woziwodzki J; Schattka SO; Kollias A
    Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate cancer].
    Tanikawa T
    Rinsho Byori; 2001 Oct; 49(10):955-62. PubMed ID: 11769471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.